Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, when he expects NHS England's Clinical Priorities Advisory Group to reach a decision on the availability of the drug Ivacaftor for cystic fibrosis patients with one of the eight non-G551D gating mutations.

NHS England's Clinical Priorities Advisory Group is an advisory committee and does not make decisions.

NHS England announced on 2 July that Ivacaftor for cystic fibrosis has been approved to be routinely commissioned on the National Health Service.